Tirzepatide

From Retapedia, the free peptide encyclopedia
Medical disclaimer. This article is for informational purposes only and does not constitute medical advice. Consult a qualified clinician before considering any compound discussed below. See Retapedia : Medical disclaimer.

Summary

What it does
Tirzepatide lowers body weight by up to about 21 percent in trials and improves blood-sugar control in type 2 diabetes. It is also the first medicine approved for obstructive sleep apnea, a breathing problem during sleep. Stomach upset is common.
How it works
A weekly injection that copies two gut hormones at once, GIP and GLP-1. Both cut appetite and improve how the body handles sugar.
WADA status
Permitted under World Anti-Doping Agency (WADA) rules. Drug-tested athletes can use it.

Tirzepatide (also known as GIP/GLP-1 dual agonist) is a modified peptide studied for its effects on fat loss, weight loss, and diabetes. FDA-approved dual GIP/GLP-1 agonist (Mounjaro/Zepbound) with superior 21% weight loss, first OSA medication, excellent diabetes control. GI side effects common.

Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist manufactured by Eli Lilly as Mounjaro (type 2 diabetes, 2.5-15mg weekly) and Zepbound (obesity and obstructive sleep apnea, 2.5-15mg weekly). Unique imbalanced agonist with greater GIP receptor engagement than GLP-1, plus biased GLP-1 agonism favoring cAMP generation over β-arrestin recruitment, enhancing insulin secretion. SURMOUNT trials demonstrated exceptional weight loss: 20.9% at 72 weeks (15mg dose), with 50-57% of participants achieving ≥20% weight loss.

Natty status
Tirzepatide is generally regarded as compatible with natural bodybuilding, though competitive federations may differ. See § Natty status.
Contents [hide]
  1. 1 Overview
  2. 2 Mechanism of action
  3. 3 Reported effects
  4. 4 Dosage and administration
  5. 5 Natty status
  6. 6 Research
  7. 7 Related compounds
  8. 8 Frequently asked questions
  9. 9 References
  10. 10 External links

Overview

SURMOUNT-4 showed 25.3% mean weight reduction long-term.

Unprecedented diabetes efficacy in SURPASS trials with HbA1c reductions of 1.9-2.6% and weight loss of 6.6-13.9kg, superior to semaglutide 1mg.

December 2024 FDA approval as first medication for moderate-to-severe obstructive sleep apnea in adults with obesity, reducing breathing disruptions by 25-29 per hour (5x more effective than placebo).

Cardiovascular meta-analysis showed HR 0.80 for MACE-4, with SURPASS-4 showing HR 0.50 at 15mg dose.

Common side effects are gastrointestinal (nausea, vomiting, diarrhea 16.24% vs 8.63% placebo), typically mild-to-moderate, transient, occurring during dose escalation. 2024 systematic review found no association with pancreatitis.

Gradual titration every 4 weeks (2.5mg steps) minimizes adverse events.

Available in 6 strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg.

Mechanism of action

Dual GIP/GLP-1 agonist. Reduces appetite for up to 21% weight loss. Improves blood sugar and diabetes control. First drug approved for obstructive sleep apnea. GI side effects common.

Reported effects

Effects reported in the literature and from preclinical models include:

  • Tirzepatide is approved by the U.S. Food and Drug Administration for long-term obesity management. [7] FDA approved
  • In a phase 3b randomized head-to-head trial in adults with overweight or obesity, tirzepatide reduced body weight by 20.2% at 72 weeks versus 13.7% with semaglutide. [8] Phase III
  • In a network meta-analysis of 262 randomized trials of obesity drugs, tirzepatide reduced body weight by 14.9% more than lifestyle modification alone at one year and reduced fat mass by 25.7%, though it also reduced lean mass by 8.3% and was among the drugs that most increased gastrointestinal adverse events. [5] Phase III
  • Clinical data show dose-dependent HbA1c reductions of 20.4-28.2 mmol/mol and weight reductions of 5-20.9% over 72 weeks, with better glycemic control and weight loss than comparator treatments in the SURPASS and SURMOUNT trial programs. [2][4] Phase II
  • In the SUMMIT randomized trial in obesity-related heart failure with preserved ejection fraction, tirzepatide reduced the composite of cardiovascular death or worsening heart failure events and improved symptoms, functional class, and quality of life. [1][6][9] Phase II
  • In randomized trials in obese patients with obstructive sleep apnea, dual GLP-1/GIP receptor agonist therapy reduced the apnea-hypopnea index alongside weight loss. [3] Phase II

Evidence grades: FDA approvedApproved (non-US)Phase IIIPhase IIPhase IPreclinicalAnecdotal

Dosage and administration

⚠
Dosage information is included for encyclopedic purposes only. Retapedia does not provide medical advice. See Retapedia : Medical disclaimer.

General

  • Week 1-4: 2.5mg once weekly (subcutaneous, starting dose)
  • Week 5-8: 5.0mg once weekly
  • Week 9-12: 7.5mg once weekly (optional step)
  • Week 13-16: 10mg once weekly
  • Week 17-20: 12.5mg once weekly (optional step)
  • Week 21+: 15mg once weekly (maximum dose)
  • Escalate by 2.5mg every 4 weeks minimum
  • Do not increase faster than 2.5mg per 4 weeks

Maintenance

  • 5mg, 10mg, or 15mg based on response/tolerability

Available strengths

  • 2.5, 5, 7.5, 10, 12.5, 15mg per 0.5mL

Natty status

See also: Peptide § Natty status

Tirzepatide is generally regarded as compatible with the natty designation, particularly when used for therapeutic healing purposes. Opinions vary across natural bodybuilding federations, and athletes who compete should consult the rulebook of their respective sanctioning body.[10]

Research

134 active clinical trials on record — highest phase: Phase 4. 311 registered in total , of which 97 completed
View on ClinicalTrials.gov · fetched Oct 5, 2026

The peptide has been the subject of 65 studies and reference works collected on this site. Additional bibliography is in § External links below.

Other peptides in this catalogue with overlapping mechanisms or status:

Ozempic Natty
Reduces appetite and slows digestion for 15-21% weight loss. Improves blood sugar control. Lowers heart attack and stroke risk by 20%.
Retatrutide Not natty
Triple agonist that curbs appetite and raises energy expenditure for 24% weight loss. Improves blood sugar, lowers blood pressure, and normalizes liver fat. Investigational; not FDA-approved.
MOTS-c Not natty
Mitochondrial-derived peptide that activates AMPK to improve insulin sensitivity and reproduce exercise-like metabolic adaptations in preclinical models. Investigational and WADA-banned; no approved human use.
5-Amino-1MQ Not natty
Oral small-molecule NNMT inhibitor that raises NAD+ and S-adenosyl methionine to boost fat-cell energy expenditure. Studied only in rodents for fat loss; no human trials exist.

Frequently asked questions

What is Tirzepatide?

FDA-approved dual GIP/GLP-1 agonist (Mounjaro/Zepbound) with superior 21% weight loss, first OSA medication, excellent diabetes control. GI side effects common.

What is Tirzepatide used for?

Tirzepatide lowers body weight by up to about 21 percent in trials and improves blood-sugar control in type 2 diabetes. It is also the first medicine approved for obstructive sleep apnea, a breathing problem during sleep. Stomach upset is common.

How does Tirzepatide work?

A weekly injection that copies two gut hormones at once, GIP and GLP-1. Both cut appetite and improve how the body handles sugar.

Is Tirzepatide natty?

Tirzepatide is generally regarded as compatible with natural bodybuilding. Most sanctioning bodies do not prohibit its therapeutic use, though rules vary by federation.

Is Tirzepatide banned by WADA?

No. Tirzepatide is permitted under World Anti-Doping Agency (WADA) rules. Intravenous infusion above the volume limit of WADA method M2.2 is restricted whatever is infused, and the list is revised every year, so check the current edition before competing.

How is Tirzepatide administered?

Tirzepatide is typically administered via: subcutaneous injection. Dosage and administration protocols vary; see the Dosage section for details.

References

  1. ^ GLP1 receptor agonists in heart failure with preserved ejection fraction (HFpEF) - beyond weight loss: a condensed scientific review. Recent review
  2. ^ Tirzepatide. Recent review
  3. ^ [The role of obesity and weight reduction in obstructive sleep apnea]. Recent review
  4. ^ Tirzepatide as a multi-organ integrator in metabolic diseases: a review of molecular mechanisms and clinical translation. Recent review
  5. ^ Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. Recent review
  6. ^ Glucagon-Like Peptide-1 (GLP-1)-Based Therapies and Heart Failure Outcomes: A Scoping Review of Contemporary Randomized Controlled Trials. Recent review
  7. ^ Pharmacological management of obesity: Current landscape and emerging therapies. Recent review
  8. ^ Comparative Efficacy and Safety of Tirzepatide Versus Semaglutide for Obesity: A Systematic Review. Recent review
  9. ^ Cardiovascular protection beyond glucose lowering: GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonism in contemporary cardiology. Recent review
  10. a b World Anti-Doping Agency. (2026). Prohibited List 2026.

External links

Categories: Peptides | Therapeutic peptides | Fat loss | Weight loss | Diabetes | Cardiovascular

This page was last updated on October 5, 2026, at 07:31 (UTC).

Research last reviewed on October 5, 2026.

Text is available under the Creative Commons Attribution-ShareAlike License; additional terms may apply.